Weekly international regulatory approvals, licensing collaborations, mergers & acquisitions, clinical developments, and financial performance of top global pharmaceutical companies — July 27 to August 2, 2026

Below is a summary of international regulatory approvals, licensing collaborations, mergers & acquisitions, clinical developments, and financial performance for the top 30 global pharmaceutical companies during the week of July 27 to August 2, 2026. International Regulatory Approvals: • Johnson & Johnson: On July 28, J&J announced the first robot-assisted bronchoscopy procedure in the Middle East using its MONARCH platform, performed at Cleveland Clinic Abu Dhabi in the UAE. This inaugural procedure utilized MONARCH QUEST—the latest upgrade to the MONARCH navigation system—featuring AI algorithms designed to enhance user experience and enabling seamless integration with various mobile and fixed advanced imaging systems. The MONARCH platform’s robot-assisted bronchoscopy enables minimally invasive access and visualization of airways, supporting clinicians in performing biopsies of suspicious pulmonary nodules. • Johnson & Johnson: On July 30, J&J announced that the U.S. FDA granted Priority Review to the Biologics License Application (BLA) supplement for subcutaneous RYBREVANT FASPRO (amivantamab hyaluronidase), for adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This dual-targeting therapy simultaneously inhibits epidermal growth factor receptor (EGFR) and mesenchymal–epithelial transition factor (MET), while also engaging the immune system. Priority Review was based on results from the pivotal Phase 1b/2 OrigAMI-4 trial, which demonstrated a 42% objective response rate to monotherapy subcutaneous administration, with over one-third of responders achieving complete remission. The trial excluded patients with HPV-associated oropharyngeal SCC and those previously treated with anti-EGFR therapy. Key findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and concurrently published in the Journal of Clinical Oncology. • Pfizer: On July 29, Pfizer and BioNTech SE announced that the European Commission has granted marketing authorization for the 2026–2027 COVID-19 vaccine formulation targeting the XFG variant—a sublineage of the JN.1 SARS-CoV-2 strain—for active immunization against coronavirus disease 2019 (COVID-19) in individuals aged six months and older. • AbbVie: On July 29, AbbVie announced that the European Commission has approved RINVOQ (upadacitinib, 15 mg once daily) for the treatment of non-segmental vitiligo (NSV) in adults and adolescents aged 12 years and older who are candidates for systemic therapy. Approval was based on data from the Phase 3 Viti-Up clinical program (M19-044), which met both co-primary endpoints at Week 48 with statistically significant and clinically meaningful improvements in total-body vitiligo area scoring index (T-VASI 50) and facial vitiligo area scoring index (F-VASI 75) versus placebo. A key secondary endpoint—stabilization of disease extent assessed by T-VASI among patients with active, progressive disease at baseline—was also achieved.

Financial news on July 29, 2026

1. SK Hynix released its Q2 2026 financial results, reporting an operating profit of KRW 60.54 trillion—below market expectations. The company announced a significant expansion of HBM4 high-bandwidth memory production in the second half of 2026 and signed long-term supply agreements with over ten technology firms. 2. Seagate Technology reported Q4 FY2026 revenue of USD 3.63 billion, up 48% year-on-year; adjusted earnings per share substantially exceeded institutional consensus estimates, driven by sustained strong demand for enterprise storage products. 3. Corning reported Q2 sales of USD 4.74 billion, up 17% year-on-year; however, it lowered its Q3 sales outlook amid slowing growth in its consumer electronics glass business. 4. xAI officially launched the Grok Build beta feature, enabling users to generate websites and small applications via natural-language prompts; currently available exclusively to premium subscribers. 5. Boeing reported Q2 2026 revenue of USD 24.6 billion, up 8% year-on-year, with operating cash flow turning positive—but recorded a net loss of USD 428 million, primarily attributable to delays and cost overruns in the Air Force One program. 6. Apple plans to launch new Apple TV and HomePod Mini models this fall, both featuring an upgraded Siri large language model, as part of its renewed push into smart home hardware—positioning itself competitively against Amazon and Google’s smart home ecosystems. 7. Nokia is expanding its optical communications business, intensifying R&D investment in high-speed data center optical modules to meet surging global demand for AI compute infrastructure. 8. Blackstone Group announced an expanded acquisition plan for North American energy storage assets, committing over USD 21 billion to renewable energy investments over the next three years. 9. Novo Nordisk raised its full-year guidance for weight-loss drug sales; construction of its expanded manufacturing facility in France continues, with global production capacity expected to increase by 60% by 2027. 10. BHP updated its mineral exploration budget, increasing planned exploration spending by 40% over the next five years—with focused efforts on lithium and copper resources critical to the new energy transition in South America and Australia. 11. The Bank of Canada released its economic assessment report: energy exports continue to support trade data, but household consumption recovery remains weaker than anticipated; monetary policy remains on hold. 12. Morgan Stanley raised its forecast for global AI hardware market growth, projecting a 45% year-on-year expansion in 2026, with robust demand persisting for optical interconnects and high-end semiconductors. 13. France is advancing implementation of its windfall tax on energy companies, directing collected revenues toward direct subsidies for households; cumulative disbursements have surpassed EUR 12 billion. 14. German economic institutions assessed the impact of nuclear phase-out, accelerating deployment of energy storage projects to compensate for electricity supply gaps left by decommissioned nuclear plants. 15. State Bank of India’s (SBI) public mutual fund IPO attracted participation from 32 international asset management firms; proceeds will fund expansion across South Asian financial markets. 16. L’Oréal’s Southeast Asia R&D center for cosmetic ingredients has entered civil construction phase, aiming to develop skincare ingredients tailored to tropical skin types, with commissioning scheduled for 2028 to serve the Asia-Pacific market. 17. Ericsson continues expanding its 5G base station network across Europe; 5G-related revenue rose 18% year-on-year in H1, with strategic focus on computing and communication infrastructure for industrial parks.

Balchem Releases Q3 2026 Financial Results

Oct 23, 2026

Balchem Corporation reported Q3 2026 financial results that met Wall Street expectations, with revenue rising 8.6% year-over-year to $290.7 million, driven by growth in its Human Nutrition and Health segment.

AlphaStreet

2026-03-22

BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms

2026-03-27

Balchem Reports €0.0 Million NonCurrent Deferred Revenue as of December 2025

2026-04-09

Balchem Corp. Stock Valuation Revised Amid Competitive FMCG Landscape

2026-04-11

Balchem Reports $581 Million Gross Property, Plant and Equipment as of December 2025

2026-04-16

Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya